Das Klinikum

Jonas Scheid

Jonas Scheid

PhD Student

Kontakt

Telefonnummer: 07071 29-87727

E-Mail-Adresse: jonas.scheid@uni-tuebingen.de

Klinik / Institut / Zentrum

  • 2022Doktorand
  • Tegeler, Christian M., et al. "HLA-DR presentation of the tumor antigen MSLN associates with clinical outcome of ovarian cancer patients." Cancers 14.9 (2022): 2260.
  • Bauer, Jens, et al. "The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma." Nature Communications 13.1 (2022): 6401.
  • Heitmann, Jonas S., et al. "Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency." Nature Communications 14.1 (2023): 5032.
  • Goyal, Ashish, et al. "DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts." Nature communications 14.1 (2023): 6731.
  • Hoenisch Gravel, Naomi, et al. "TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification." Nature Communications 14.1 (2023): 7472.
  • Beltrao, Pedro, et al. "Proceedings of the EuBIC-MS developers meeting 2023." Journal of Proteomics 305 (2024): 105246.
  • Velz, Julia, et al. "Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics." Nature Communications 16.1 (2025): 1364.
  • Declercq, Arthur, et al. "TIMS2Rescore: A Data Dependent Acquisition-Parallel Accumulation and Serial Fragmentation-Optimized Data-Driven Rescoring Pipeline Based on MS2Rescore." Journal of Proteome Research (2025).
  • Lemke, Steffen, et al. "PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development." Journal for Immunotherapy of Cancer 13.4 (2025): e011366.